Sustaining Remission From PTSD Using Tuned Vibroacoustic Stimulation (TVS) Following MDMA-Assisted Psychotherapy

Description

The purpose of this research is to examine a wearable device called Apollo that emits gentle vibrations found to benefit mood, energy, and focus. We want to understand how it affects outcomes related to MDMA-assisted psychotherapy for PTSD including depression, anxiety and emotion regulation. This study will test whether regular use of the Apollo wearable improves rates of sustained symptom remission in PTSD following MDMA-assisted psychotherapy over the course of two years

Conditions

Stress Disorders, Post-Traumatic

Study Overview

Study Details

Study overview

The purpose of this research is to examine a wearable device called Apollo that emits gentle vibrations found to benefit mood, energy, and focus. We want to understand how it affects outcomes related to MDMA-assisted psychotherapy for PTSD including depression, anxiety and emotion regulation. This study will test whether regular use of the Apollo wearable improves rates of sustained symptom remission in PTSD following MDMA-assisted psychotherapy over the course of two years

Sustaining Remission From Posttraumatic Stress Disorder (PTSD) Using Tuned Vibroacoustic Stimulation (TVS) Following MDMA-Assisted Psychotherapy

Sustaining Remission From PTSD Using Tuned Vibroacoustic Stimulation (TVS) Following MDMA-Assisted Psychotherapy

Condition
Stress Disorders, Post-Traumatic
Intervention / Treatment

-

Contacts and Locations

Pittsburgh

Apollo Neuroscience, Inc., Pittsburgh, Pennsylvania, United States, 15219

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Age 18 or over
  • * Completion of the MAPS MDMA-Assisted Psychotherapy for PTSD clinical trial (treatment cohort)
  • * completion of the MAPS MDMA-Assisted Psychotherapy for PTSD clinical trial (placebo cohort)
  • * enrolled in the MAPS MDMA-Assisted Psychotherapy for PTSD clinical trial, but dropped out
  • * Unable to give adequate informed consent
  • * Have any current problem which, in the opinion of the investigator might interfere with participation
  • * Are unable to complete questionnaires written in English

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Apollo Neuroscience, Inc.,

Belinda Tan, MD PhD, PRINCIPAL_INVESTIGATOR, The Board of Medicine

Study Record Dates

2025-12-31